Table 1

Baseline characteristics of patients included in the analysis of predictors of outcomes and those excluded due to incomplete data. Values are median (IQR) or n (%), unless otherwise stated

All n=60Subgroup for Analysis of predictors of outcome
Included n=41Excluded n=19p Value
Age, mean (SD)46 (14)45 (15)48 (11)0.4
Female39 (65%)27 (66%)12 (63%)0.8
Symptom duration, months9 (4–17)9 (4–18)8 (4–17)0.8
ACPA positive4 (7%)3 (7%)1 (5%)1.0
Early Morning Stiffness ≥60 min31 (52%)19 (46%)12 (63%)0.3
3 (2–6)a
2 (1–4)a
3 (2–6)
2 (1–5)
2 (1–3)a
2 (1–3)a
CRP, mg/L7 (0–23)6 (0–22)10 (0–27)0.4
Patient VASDA, mm43 (25–66)a+b45 (25–68)b34 (17–63)a0.7
DAS-CRP2.3 (1.6–2.9)b+c2.3 (1.8–2.9)b1.8 (1.3–2.5)c0.2
HAQ0.3 (0.1–0.9)a+d0.3 (0.1–0.9)d0.6 (0.1–1.1)a0.9
US of 26 joints at baseline: total GS score9 (5–16)e9 (5–17)NAeNA
Total PD score1 (0–2)e1 (0–2)NAeNA
Number of joints with GS≥ grade 2
Number of joints with PD≥ grade 1
2 (1–5)e
1 (0–1)e
2 (1–5)
1 (0–1)
Fulfilment of 2010 ACR/EULAR RA criteria with joint involvement determined clinically or by GS≥ grade 2 and/or PD≥ grade 14/42 (10%)4 (10%)NAeNA
Radiographic erosion in the hands and/or feet4/55 (7%)3 (7%)1 (7%)f1.0
  • Missing data in a12, b8, c13, d6, e18 and f5 cases.

  • ACPA, anti-cyclic citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C reactive protein; DAS-CRP, disease activity score; EULAR, European League Against Rheumatism; GS, grey scale; HAQ, Health Assessment Questionnaire; NA, not applicable (summary statistics not performed due to insufficient data); PD, power Doppler activity; RA, rheumatoid arthritis;RAI, Ritchie articular index; SJC44, swollen joint count of 44 joints; US, ultrasound; VASDA, visual analogue scale disease activity assessment.